Pre-clinically, Mre11 depletion or blockade not only reversed platinum resistance, but targeting Mre11 in XRCC1 deficient platinum sensitive ovarian cancers also induced synthetic lethality. This evidence concerns the gene XRCC1 and ovarian carcinoma.